Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Up 58.7% in October

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was the target of a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 160,100 shares, a growth of 58.7% from the October 15th total of 100,900 shares. Based on an average trading volume of 117,900 shares, the days-to-cover ratio is presently 1.4 days.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on ENLV shares. EF Hutton Acquisition Co. I upgraded shares of Enlivex Therapeutics to a “strong-buy” rating in a research note on Tuesday, August 27th. HC Wainwright restated a “buy” rating and issued a $6.00 target price on shares of Enlivex Therapeutics in a research note on Friday, September 27th.

Enlivex Therapeutics Trading Down 0.9 %

Shares of NASDAQ:ENLV opened at $1.07 on Friday. The stock has a market capitalization of $22.91 million, a P/E ratio of -0.91 and a beta of 1.11. The business has a 50-day moving average price of $1.44 and a two-hundred day moving average price of $1.39. Enlivex Therapeutics has a 1-year low of $1.01 and a 1-year high of $4.59.

Enlivex Therapeutics (NASDAQ:ENLV) last posted its earnings results on Friday, August 30th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.06. As a group, equities analysts predict that Enlivex Therapeutics will post -0.7 EPS for the current year.

Institutional Investors Weigh In On Enlivex Therapeutics

Several large investors have recently made changes to their positions in the stock. Armistice Capital LLC acquired a new stake in shares of Enlivex Therapeutics in the 2nd quarter valued at approximately $2,415,000. Sigma Investment Counselors Inc. bought a new stake in Enlivex Therapeutics in the 3rd quarter valued at $50,000. Finally, XTX Topco Ltd bought a new stake in Enlivex Therapeutics in the 2nd quarter valued at $35,000. Institutional investors and hedge funds own 1.02% of the company’s stock.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.